The Role of Self-Monitoring of Blood Glucose in Patients Treated With SGLT-2 Inhibitors | Zendy

Oliver Schnell | Zendy; Hasan Alawi | Zendy; Tadej Battelino | Zendy; Antonio Ceriello | Zendy; Peter Diem | Zendy; A. Felton | Zendy; Kari Harno | Zendy; İlhan Satman | Zendy; Bruno Vergès | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Role of Self-Monitoring of Blood Glucose in Patients Treated With SGLT-2 Inhibitors

Author(s) -

Oliver Schnell,

Hasan Alawi,

Tadej Battelino,

Antonio Ceriello,

Peter Diem,

A. Felton,

Kari Harno,

İlhan Satman,

Bruno Vergès

Publication year - 2014

Publication title -

journal of diabetes science and technology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.039

H-Index - 75

eISSN - 1932-3107

pISSN - 1932-2968

DOI - 10.1177/1932296814534366

Subject(s) - medicine , intensive care medicine , continuous glucose monitoring , type 2 diabetes , diabetes mellitus , blood glucose self monitoring , type 1 diabetes , endocrinology

The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research